Nature. 2020 Jun;582(7810):73-77. doi: 10.1038/s41586-020-2338-1. Epub 2020 Jun 3.
High blood cholesterol is typically considered a feature of wealthy western countries. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular risk-changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.
高胆固醇血症通常被认为是富裕西方国家的特征。然而,全世界的血液胆固醇的饮食和行为决定因素正在迅速变化,各国使用降脂药物的比率也各不相同。这些变化会对高密度脂蛋白(HDL)胆固醇和非高密度脂蛋白胆固醇的水平产生明显影响,而这些影响对人类健康有不同的影响。然而,以前在全球分析中没有报告过这些水平随时间的变化趋势。在这里,我们汇总了 1127 项基于人群的研究,这些研究在 10260 万人中测量了血液脂质,以估计 1980 年至 2018 年期间 200 个国家的总胆固醇、非高密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平的趋势。在全球范围内,总胆固醇或非高密度脂蛋白胆固醇从 1980 年到 2018 年几乎没有变化。这是低收入和中等收入国家,特别是东亚和东南亚国家增加,高收入西方国家,特别是西北欧和中欧和东欧国家减少的净效果。因此,非高密度脂蛋白胆固醇水平最高的国家(心血管风险的标志物)发生了变化,从 1980 年的比利时、芬兰、格陵兰、冰岛、挪威、瑞典、瑞士和马耳他等西欧国家变为亚洲和太平洋地区的国家,如托克劳、马来西亚、菲律宾和泰国。2017 年,高非高密度脂蛋白胆固醇估计导致全球 390 万人(95%可信区间为 370 万至 420 万人)死亡,其中一半发生在东亚、东南亚和南亚。脂质相关风险的全球重新定位,即非最佳胆固醇从西北欧、北美和澳大拉西亚的高收入国家的显著特征转变为影响东亚、东南亚和大洋洲国家的特征,应该激励在全世界使用基于人群的政策和个人干预措施来改善营养和增强治疗的可及性。